肌少症可预测胸腹主动脉瘤手术与非手术患者的长期生存
本研究回顾性纳入2009至2017年295例胸腹主动脉瘤患者,其中199例手术、96例非手术。通过第三腰椎单层CT测量总肌肉面积并按身高标准化,以最低三分位定义肌少症。Kaplan-Meier和Cox回归显示,无论是否手术,肌少症均与更差长期生存显著相关。
要点
- 肌少症可在胸腹主动脉瘤患者中通过第三腰椎CT肌肉面积标准化定义。
- 手术和非手术组中,肌少症均独立预测更短长期生存。
- 肌少症可能有助于胸腹主动脉瘤风险分层和治疗决策。
核心结论
- 在胸腹主动脉瘤手术和非手术患者中,肌少症均与显著更低的长期生存相关。
- 肌少症可作为胸腹主动脉瘤患者生存预测指标,并可能辅助风险分层和决策。
研究设计与样本
- 回顾性队列研究,纳入2009至2017年单中心学术医院295例胸腹主动脉瘤患者,199例手术、96例非手术。
- 通过第三腰椎单层轴位CT测量总肌肉面积,按身高标准化,以最低三分位确定肌少症 cutoff 值。
主要发现
- 非手术组更常见女性、慢性肾病、冠心病、脑血管病、更高改良衰弱指数和更大主动脉直径。
- Kaplan-Meier分析显示手术和非手术组中肌少症患者长期生存均显著更低。
- Cox回归调整年龄、种族、性别、最大主动脉直径、改良衰弱指数、慢性肾病和活跃吸烟后,肌少症预测手术组更短生存(HR 0.96,95%CI 0.94-0.99,P=.006)。
- Cox回归中肌少症预测非手术组更短生存(HR 0.95,95%CI 0.90-1.00,P=.05)。
- 手术组中年龄显著预测更短生存,非手术组中吸烟和主动脉直径显著。
关键数值与推荐
- 肌少症定义为第三腰椎单层轴位CT总肌肉面积经身高标准化后的最低三分位。
- 手术组肌少症预测更短生存的HR为0.96(95%CI 0.94-0.99,P=.006)。
- 非手术组肌少症预测更短生存的HR为0.95(95%CI 0.90-1.00,P=.05)。
临床怎么用
- 对胸腹主动脉瘤患者,可利用第三腰椎CT肌肉面积评估肌少症以辅助风险分层。
- 肌少症信息可能帮助手术与非手术管理决策,但需结合年龄、吸烟、主动脉直径等因素。
局限性
- 回顾性单中心研究,样本量295例,可能存在选择偏倚。
- 肌少症 cutoff 基于本研究人群最低三分位,外推需验证。
- 非手术组肌少症预测生存的P值为.05,处于边界显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sarcopenia, defined as a loss of muscle mass or poor muscle quality, is a syndrome associated with poor surgical outcomes. The prognostic value of sarcopenia in patients with thoracoabdominal aortic aneurysms (TAAAs) is unknown. The present study was designed to define sarcopenia in this patient population and assess its impact on survival among patients who had undergone operative and nonoperative management of TAAAs. METHODS: We retrospectively reviewed all patients with a diagnosis of a TAAA at an academic hospital between 2009 and 2017 who had been selected for operative and nonoperative management. Sarcopenia was identified by measuring the total muscle area on a single axial computed tomography image at the third lumbar vertebra. The muscle areas were normalized by patient height, and cutoff values for sarcopenia were established at the lowest tertile of the normalized total muscle area. Long-term patient survival was assessed using Kaplan-Meier and Cox regression models. RESULTS: A total of 295 patients were identified, of whom 199 had undergone operative management and 96 nonoperative management for TAAAs. The patients selected for nonoperative management were more likely to be women and to have chronic kidney disease, coronary artery disease, cerebrovascular disease, a higher modified frailty index, and a larger aortic diameter. The Kaplan-Meier analyses revealed significantly lower long-term survival for the patients with and without sarcopenia in the operative and nonoperative groups. In Cox regression analyses, sarcopenia was a significant predictor of shorter survival for both operative (hazard ratio, 0.96; 95% confidence interval, 0.94-0.99; P = .006) and nonoperative (hazard ratio, 0.95; 95% confidence interval, 0.90-1.00; P = .05) groups after adjusting for age, race, sex, maximum aortic diameter, modified frailty index, chronic kidney disease, and active smoking. Additionally, age was a significant predictor of shorter survival in the operative group, and smoking and aortic diameter were significant in the nonoperative group. CONCLUSIONS: In our cohort of patients who had received operative and nonoperative management of TAAAs, the patients with sarcopenia had had significantly lower long-term survival, regardless of whether surgery had been performed. These data suggest that sarcopenia could be used as a predictor of survival for patients with TAAAs and might be useful for risk stratification and decision making in the management of TAAAs.
引用
- Ghaffarian AA, Unangst J, Bartek MA, et al. Sarcopenia predicts for long-term survival in patients with thoracoabdominal aortic aneurysms undergoing operative and nonoperative management. J Vasc Surg. 2021. PMID: 34506897. doi:10.1016/j.jvs.2021.08.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。